Orphan drug development: an economically viable strategy for biopharma R&D.
about
Rituximab: how approval history is reflected by a corresponding patent filing strategyBrand-name drug, generic drug, orphan drug. Pharmacological therapy with biosimilar drugs - provision of due diligence in the treatment processOpportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuriaProfitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control StudyShining a light in the black box of orphan drug pricingThe economic burden of fragile x syndrome: healthcare resource utilization in the United States.Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework.Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.What Is the Purpose of the Orphan Drug Act?Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.Impact of orphan drugs on Latvian budget.Sustainable rare diseases business and drug access: no time for misconceptions.Funding innovation for treatment for rare diseases: adopting a cost-based yardstick approach.Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?Clinical trials in rare disease: challenges and opportunities.Orphan drugs policies: a suitable case for treatment.The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity?Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review.Quantifying the persisting orphan-drug shortage public health crisis in the United StatesA personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?Affordable orphan drugs: a role for not-for-profit organizations.Developing gene and cell therapies for rare diseases: an opportunity for synergy between academia and industry.The use of 2D fingerprint methods to support the assessment of structural similarity in orphan drug legislation.When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada.Exploring patient and family involvement in the lifecycle of an orphan drug: a scoping review.Engagement of Canadian Patients with Rare Diseases and Their Families in the Lifecycle of Therapy: A Qualitative Study.Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications.Are Phage Lytic Proteins the Secret Weapon To Kill Staphylococcus aureus?Orphan drugs: Indian perspective.Workshop Proceedings: Streamlined Development of Safety Assessment Programs Supporting Orphan/Rare Diseases-Are We There Yet?Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.Orphan Drugs and Potential Novel Approaches for Therapies of β-Thalassemia: Current Status and Future ExpectationsCharacteristics of clinical trials in rare vs. common diseases: A register-based Latvian study.Drivers of Orphan Drug Development
P2860
Q26821872-5CA754BA-4F1D-4318-88BE-4510215F6307Q27006884-EA3D3DD1-29A9-4A92-B14F-B572171224FBQ28243221-31B1B159-2C79-46B5-B3E0-9A08D26C19CBQ28552860-B0E1B4DC-040A-4A47-BBDE-911E2625422FQ33602241-29FFA857-BEAE-4CE0-9893-4BD93766ED56Q33652798-5E9EF2D6-4E61-4B4F-958D-7D726A80AD28Q35126801-D2DFD306-03DF-4EA2-BA28-AA3C4D428DF9Q35167117-964A905E-F157-4A9D-BDE0-B23A4BC4BD08Q36237799-CFB8D050-989A-4438-A960-83F567B5E32FQ36788287-BD2C2376-5D74-4F44-A416-F96888B87ADEQ36895393-B4081F9E-424D-45C3-B107-7BCAF6B0EA55Q37075327-142A1949-B7E1-4D89-8FC9-5A16C1EA9D04Q37321675-E84BE2CE-26AB-40D2-937B-AA33346A7AE3Q37566934-26353D41-94AA-44B5-9081-0DC7BCF2BFA7Q37659610-6D494790-E63B-4B09-A376-FC1C8BC3B81AQ38179281-AD522E2C-DEAF-4032-85D7-ED07D3B95132Q38211832-555DE570-1FEC-4F6B-8EFE-1F7F72667410Q38291431-E097965F-9AF6-44F5-9611-4605A549E5ECQ38564601-31762BB2-F4F3-45A8-BFE9-BF8C74178FC2Q38609235-6CE22BE1-A564-4D81-8719-2D418702B383Q38981163-44F4023A-C7D0-42F0-9909-A22B3E7C8784Q39008609-67C17D10-8AA5-438C-8479-53AD7FDB6990Q39293475-42D2E55E-329F-41FA-B899-72C97B9EB808Q41952646-328AE587-2128-4C6D-8EC6-F33743ED2115Q45754296-97380553-B4AD-44F0-82E6-099C2E561698Q47159898-FE65C61D-C1A8-41FD-BAC7-18A4622E0C30Q47211277-B46641DD-7944-44DD-9C91-03AD857825F1Q47566445-B2E60E30-7174-4CFE-89FF-09F045B231BAQ48181608-B7EEBDC4-ED38-481D-9859-0EC83D532E89Q49725754-2C5921AC-1755-439A-A142-2CA12F199F1BQ50506337-5B94DA46-6AC2-402C-9135-839816F3FCFFQ50918560-C12264EA-1CAC-4BBC-BFAE-CFF9A94EAC3CQ54585888-3087C375-A712-4025-B0AD-BB0CAAA6BF6CQ55329890-9D0A84DA-4345-4F40-9B07-879FDB28D5AFQ57818363-FD1C12C6-7A91-4244-B501-86CD7B95D2D6
P2860
Orphan drug development: an economically viable strategy for biopharma R&D.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Orphan drug development: an economically viable strategy for biopharma R&D.
@ast
Orphan drug development: an economically viable strategy for biopharma R&D.
@en
Orphan drug development: an economically viable strategy for biopharma R&D.
@nl
type
label
Orphan drug development: an economically viable strategy for biopharma R&D.
@ast
Orphan drug development: an economically viable strategy for biopharma R&D.
@en
Orphan drug development: an economically viable strategy for biopharma R&D.
@nl
prefLabel
Orphan drug development: an economically viable strategy for biopharma R&D.
@ast
Orphan drug development: an economically viable strategy for biopharma R&D.
@en
Orphan drug development: an economically viable strategy for biopharma R&D.
@nl
P2093
P1433
P1476
Orphan drug development: an economically viable strategy for biopharma R&D.
@en
P2093
Cory S M Williams
John E Arrowsmith
Kiran N Meekings
P304
P356
10.1016/J.DRUDIS.2012.02.005
P577
2012-02-17T00:00:00Z